Abstract 116P
Background
Precision medicine, a tailored approach based on tumor profiling and actionable genetic mutations detection, is the new paradigm for oncologic patients management. An increasing number of genes is tested after new targeting drug approvals with high impacts in terms of costs and report turnaround time.
Methods
Using Diaceutics Data Repository, a global multi source database including commercial claims and laboratory data, we analyzed testing and positivity rate to compare the 2022 and 2023 diagnostic activity of the laboratory.
Results
2023 data analysis reveals NGS as the primary method used currently for the majority of tumors such as lung (90%), colorectal cancers (70%) and melanoma (78%) while in 2022 the sequential testing approach by real time PCR and FISH was the standard approach for all samples. Following the approval of new drugs in 2022, the laboratory also covers in 2023 new disease entities by NGS testing such as cholangiocarcinoma and endometrial cancer. Immunohistochemistry also encountered consistent changes: ALK5A4 antibody is now only used as a confirmatory tool for ALK gene rearrangements (previously detected by molecular testing); PAN-TRK antibody used for NTRK genes fusions screening increased and PD-L1 testing is also performed in colorectal, melanoma, head and neck squamous cancers in addition to lung adenocarcinoma.
Conclusions
Our laboratory successfully experienced a switch to NGS sequencing technology in a very short time. An automated system for library preparation was shown to be helpful for results standardization and sample tracking in a laboratory not so experienced in molecular approaches. We also demonstrated that little customized panels are suitable to detect actionable genetic alterations as recommended by International Guidelines. A parallel sequencing approach introduced in the routine of a middle size public pathology laboratory is possible and cost effective.
Editorial acknowledgement
We would like to thank Diaceutics PLC who provided data and analytic support on their DXRX platform for this research.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
20P - Effects of <italic>Apis dorsata</italic> honey on the expression of selected CYP450, pro-apoptotic, and anti-apoptotic genes during induced cytotoxicity in cyclophosphamide-treated human lung carcinoma (A549) cells
Presenter: Jose Kenneth Narag
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Hsa_circ_0009061 inhibits the progression of bladder cancer through the miR-889-3p/CPEB3 axis
Presenter: Minkang Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Exploring exportin-1 as a therapeutic vulnerability in lung squamous cell carcinoma
Presenter: Vidushi Durani
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Identification of HPSE as potential novel therapeutic target for lung adenocarcinoma patients
Presenter: Samuel Doré
Session: Cocktail & Poster Display session
Resources:
Abstract
24P - High-throughput plasma proteomics profiling in early breast cancer
Presenter: Isabella Lombardo
Session: Cocktail & Poster Display session
Resources:
Abstract
25P - Immunohistochemical analysis of ROR1 and BMI-1 expression in luminal breast cancer
Presenter: Sergey Vtorushin
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Associations between cancer stem cells (CSC) markers and androgen (AR) and estrogen (ER) receptors expression in prostate cancer (PCa)
Presenter: Marina Puchinskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Proteomic profiling reveals organ-specific differences in metastases and identifies potential biomarkers for recurrence risk in localized colon cancer
Presenter: Blanca García-Micó
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Collagen-activated signalling pathway is significantly hypermethylated in high-grade serous ovarian cancer (HGSOC) patients treated with platinum-containing neoadjuvant chemotherapy (NACT)
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - Quantitative tissue analysis reveal adenylate kinase 2 protein signatures: Therapeutic target for meningioma
Presenter: Rashmi Rana
Session: Cocktail & Poster Display session
Resources:
Abstract